Peginterferon Lambda News Today

Several trial participants experienced concerning hepatobiliary events.

One hepatitis delta virus player (HDV) has dropped out after Eiger Biopharmaceuticals Inc.’s phase III effort with peginterferon lambda turned up safety issues, while others remain busy in a space highlighted during last November’s meeting of the American Association for the Study of Liver Diseases. Shares of Palo Alto, Calif.-based Eiger (NASDAQ:EIGR) closed Sept. 13 at 41 cents, down 28 cents, or 40.6%, on word that the company is stopping the Limt-2 study in patients with chronic HDV.

The discontinuation of LIMT-2 was announced after 4 patients experienced hepatobiliary events resulting in liver decompensation during the phase 3 study of peginterferon lambda for HDV.

Eiger BioPharmaceuticals, Inc. (EIGR), a commercial-stage biopharmaceutical company focused on rare metabolic diseases, Wednesday said it has decided to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta or CHD.

Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced it would focus its development efforts on advancing avexitide in 

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

The data look quite promising and other treatments have now fallen by the wayside, said Paul Sax, MD, of Brigham and Womens Hospital in Boston.

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

Scale The Eiger With This 'Sum of the Parts Trade...EIGR

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...